Literature DB >> 6407751

Differential potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine in chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro.

S M Oredsson, P J Tofilon, B G Feuerstein, D F Deen, M L Rosenblum, L J Marton.   

Abstract

alpha-Difluoromethylornithine, an enzyme-activated, irreversible inhibitor of ornithine decarboxylase, inhibited the growth of both chloroethylnitrosourea-sensitive and -resistant 9L rat brain tumor cells in vitro. After 48 hr of treatment with 10 mM alpha-difluoromethylornithine, the putrescine and spermidine contents of both resistant and sensitive cells were less than 5% of control levels, but the spermine level was slightly elevated. The cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea, as measured by a colony-forming efficiency assay, was significantly increased in alpha-difluoromethylornithine-pretreated sensitive cells but not in resistant cells treated with this polyamine inhibitor. With the sister chromatid exchange assay, we found that alpha-difluoromethylornithine pretreatment increased 1,3-bis(2-chloroethyl)-1-nitrosourea-induced damage to chromosomes in sensitive but not in resistant cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407751

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.

Authors:  J Seidenfeld; K A Komar; M F Naujokas; A L Block
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  DNA topoisomerase II as a target of antineoplastic drug therapy.

Authors:  L A Zwelling
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

3.  The growth-inhibitory effect of 4-hydroperoxycyclophosphamide against human non-small cell lung carcinoma is enhanced by low-dose difluoromethylornithine.

Authors:  D C Tsai; G D Luk
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.